Insights

Jorge Cortes, MD shares recent progress in the treatment of chronic myeloid leukemia, highlighting the use of asciminib for patients including those who have not responded to other tyrosine kinase inhibitors.

Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.

At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.

Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.

At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.

Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.

At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.

At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...

At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.

At the 2025 Great Debates in Hematologic Malignancies meeting, Aaron Goldberg, MD, PhD, discussed evolving treatment strategies and therapies for patients with relapsed/ refractory acute myeloid leukemia.